enGene chairman Glickman resigns; Heffernan appointed chair; BLA submission planned for 2H 2026

enGene Therapeutics Inc.

Dr. Richard Glickman resigned as director and chairman effective July 15, 2026; no disagreement.
Michael Heffernan appointed as chairman; he has over 30 years biopharma experience.
Pre-BLA meeting with FDA and BLA submission for detalimogene planned for 2H 2026.
Potential FDA approval of detalimogene in 2027.
Detalimogene is being evaluated in Phase 2 LEGEND trial for high-risk NMIBC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.